There is a critical need for new therapies for T-cell lymphomas, and with ongoing trials of mTOR and aurora kinase inhibitors, PI3K inhibitors, and others, new options may be on the horizon.
In this interview we discuss the latest therapy developments in the treatment of multiple myeloma.
A handful of novel antibody-based therapies may soon emerge for the treatment of acute myeloid leukemia, according to a presentation at the 21st Annual International Congress on Hematologic Malignancies.
Significant progress has been made in the treatment of chronic lymphocytic leukemia with the addition of options such as the tyrosine kinase inhibitor ibrutinib, the monoclonal antibody obinutuzumab, and the BCL2 inhibitor venetoclax.
In this interview we discuss clinical developments in essential thrombocythemia, polycythemia vera, and myelofibrosis, as well as the latest treatment options.
New treatment options are now available for light-chain amyloidosis, with additional ones on the way, according to a presentation at the 21st Annual International Congress on Hematologic Malignancies.